Ashish M. Kamat, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center, shared his recent article on X:
“Join us March 21st for the 8th edition of Rapid Fire Debates in Bladder Cancer at EAU 2025.
A poll to help our debaters:
For High Risk NMIBC in 2025 – Is BCG still the best option (assuming NO shortage)?
Option a- Yes, BCG is still king
Option b- No, time to dethrone BCG.”